Large Scale Biology Corporation Will Preview New Research Product and Announce Scientific News in Three Areas at Annual American Society of Hematology Conference.

Business Editors and Health/Medical Writers

Annual American Society of Hematology Conference

Booth No. 888

ORLANDO, Fla.--(BW HealthWire)--Dec. 7, 2001

The 43rd Annual Meeting and Exposition of the American Society of Hematology (ASH), which begins here this evening, will be the preview launching site for a new research product from Large Scale Biology Corporation (Nasdaq:LSBC) and the forum for announcements of important scientific advances by LSBC scientists in hematology, oncology and immunotherapy. The thrust of the combined news announcements is "the best evidence that LSBC has made substantial progress in developing products that will meet the needs of patients and of the commercial research market through steady investment in the work of a remarkable research team," says LSBC Chairman and CEO Robert L. Erwin.

New cell expansion product

During the five-day conference, LSBC will offer a first preview of its stabilized formulation of the hematopoietic growth factor EDHF (Endothelium-Derived Hematopoietic Factor), which the Company plans to commercialize by the end of March 2002 under the name PLURIGEN(TM) CM. The utility of the product for non-clinical research is expected to demonstrate LSBC's previously unrecognized proprietary capabilities of increasing progenitor cell content in bone marrow and of enhancing manufacturing efficiency of various human cells, and what the Company's president John D. Fowler, Jr. calls "a new emphasis at LSBC on product development." Information on the PLURIGEN CM product will be available at LSBC's exhibitor booth during the ASH meeting (Booth No. 888).

Technical Presentations and Their Significance

During the conference, two LSBC scientists will make four presentations on the Company's latest advances in hematology, oncology and immunotherapy.

Alison McCormick, Ph.D., Senior Scientist, will present LSBC's work on personalized cancer vaccines. Produced by LSBC's proprietary GENEWARE(R) technology, these vaccines show remarkable tumor specificity and prove the feasibility of customizing therapy to the needs of individual patients. Dr. McCormick will also report on the excellent safety profile observed to date with LSBC's vaccines administered to human patients in an ongoing Phase I clinical trial. "Based on encouraging, preliminary response data from the first cohorts of the Phase I study, we are making the commitment to conduct one or more Phase II studies during 2002," stated Robert Erwin. Dr. McCormick will update the latest results from the personalized cancer vaccines program, including the ongoing clinical trial, on Monday, December 10 at 9:15 a.m., Abstract No. 1949, Hall F-5.

In a subsequent presentation, Dr. McCormick will report positive results from tests of LSBC's proprietary hematopoietic growth factor, EDHF, as a stimulant of the immune response in preclinical cancer vaccine animal studies. That presentation will take place on Monday, December 10, 11:15 a.m., Abstract No. 2930, Room 330 D.

Thomas Davis, Ph.D., Director of Immunology and Stem Cell Biology at LSBC, will present the Company's new work on the proprietary hematopoietic growth factor EDHF (Endothelium-Derived Hematopoietic Factor) and its applications. Dr. Davis will report various successful applications of EDHF for the large-scale generation of multilineage hematopoietic progenitor cells and production of large quantities of pre-dendritic myelomonocytic progenitor cells reliably from human CD34+ hematopoietic cells in vitro and murine progenitor cells in vivo.

This research demonstrates that these generated progenitor cells can be efficiently converted to highly pure populations of autologous ("self") antigen-presenting cells (dendritic cells) which may prove clinically useful in various immune cell-based vaccination strategies for the treatment of infectious diseases and malignancies. Dr. Davis will report on this work at 4:30-6:00 p.m. on Sunday, December 9 (Abstract No. 1172, Poster No. 277) and at 5:15-6:30 p.m. on Monday, December 10 (Abstract No. 2707, Poster No. 692), both in Hall C.

A related presentation on hematopoiesis will be made by John Chute, M.D., on behalf of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)/U.S. Navy Transplantation and Immunity Branch. Using a murine model, Dr. Chute has shown that co-culturing primitive human bone marrow progenitor cells with HUBEC facilitates the proliferation and engraftment of bone marrow repopulating cells in vivo. Results from this clinically relevant work will be summarized at 5:15-6:30 p.m. on Monday, December 10 (Abstract No. 2744, Poster No. 729) in Hall C.

Working initially at NMRC as a collaborator of LSBC within a cooperative research and development agreement (CRADA), Dr. Chute joined LSBC last month as Senior Director, Clinical Research. Dr. Chute was the CRADA's Principal Investigator on cellular therapy-based hematopoiesis and transplantation research. "The complementary work of Dr. Davis and Dr. Chute could impact medical research in broad fields such as stem cell transplantation, gene therapy, tolerance induction and vaccine therapy," said Dr. Leigh Anderson, LSBC's Chief Scientific Officer.

The strong presence of LSBC at the ASH Annual Meeting underscores its aggressive programs for the development of products for hematology, oncology and immunotherapy. Long-term investment strategy in these areas has focused on product categories for which LSBC anticipates considerable medical demand and long-term growth. The PLURIGEN CM cell culture product is the first in a portfolio of related inventions, which LSBC intends to produce and market with partners or independently.

About Large Scale Biology Corporation

Large Scale Biology uses its proteomics, functional genomics and biomanufacturing technologies to develop and manufacture personalized drugs, vaccines and diagnostics for rapid identification and effective treatment of disease. Corporate offices and the genomics operations are headquartered in Vacaville, Calif.; the Company's proteomics operations are located in Germantown, Md.; and the Company's bioprocessing and manufacturing facilities are located in Owensboro, Ky. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com.

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our current plans, expectations, estimates, and projections and management's beliefs about our future performance. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates" or variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and which may cause our actual results and performance to differ materially from those expressed or forecasted in any such forward-looking statements. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities Exchange Commission. Unless required by law, Large Scale Biology Corporation undertakes no obligation to update publicly any forward-looking statements.

Note to Editors: GENEWARE is a registered trademark of Large Scale Biology Corporation. LSBC(TM) and PLURIGEN CM are trademarks of Large Scale Biology Corporation.